NeuroRx Announces Phase 2 Data from NRX-101, Initiates Pivotal Study for Severe Bipolar Depression with Acute Suicidal Ideation & Behavior (ASIB)

Investors

NeuroRx is currently raising funds to support its ongoing clinical development of NRX-100/NRX-101  for the treatment of Bipolar Depression in patients with Acute Suicidal Ideation/Behavior (ASIB). If you are interested in learning more about NeuroRx and opportunities to invest in the company, please contact:


Investor Relations:

 

Solebury Trout

 

Chiara Russo - Vice President:

 

crusso@troutgroup.com

 

+1 617 221 9197 Direct

+1 617 306 9137 Cell

+1 646 378 2901 Fax

 

75 Arlington Street, Suite 5014

Boston, MA 02116

 

Brian Korb - Managing Director:

 

bkorb@troutgroup.com

 

+1 646 378 2923 Direct

+1 917 653 5122 Cell

+1 646 378 2901 Fax

 

740 Broadway, 9th Floor

New York, NY 10003

NRX-100/NRX/101 is the first sequential therapy to include an oral therapeutic in development for the treatment of Bipolar Depression in patients with Acute Suicidal Ideation/Behavior (ASIB)

Submitting Form...

The server encountered an error.

Form received.

Contact the NeuroRx Investor-Relations Team

© 2016 NeuroRx, Inc.

*These drugs are investigational and not approved by the US FDA

STAY CONNECTED